These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 34452747)
1. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747 [TBL] [Abstract][Full Text] [Related]
2. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143 [TBL] [Abstract][Full Text] [Related]
3. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112 [TBL] [Abstract][Full Text] [Related]
4. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535 [TBL] [Abstract][Full Text] [Related]
5. Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women. Agha N; Alshamsan B; Al-Farsi S; Ateya HA; Almugbel FA; Alotaibi HA; Omar A; Mohamed AS; Alharthy H; Elhassan T; Salem H; Alhusaini H BMC Cancer; 2022 Jan; 22(1):18. PubMed ID: 34980015 [TBL] [Abstract][Full Text] [Related]
6. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study. Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869 [TBL] [Abstract][Full Text] [Related]
8. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
9. Disparities between Uptake of Germline Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091 [TBL] [Abstract][Full Text] [Related]
10. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403 [TBL] [Abstract][Full Text] [Related]
11. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735 [TBL] [Abstract][Full Text] [Related]
14. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311 [TBL] [Abstract][Full Text] [Related]
16. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Casey MJ; Bewtra C Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908 [TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279 [TBL] [Abstract][Full Text] [Related]
19. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
20. Kim DH; Cho CH; Kwon SY; Ryoo NH; Jeon DS; Lee W; Ha JS J Gynecol Oncol; 2018 Nov; 29(6):e90. PubMed ID: 30207098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]